Dashboard
1
Weak Long Term Fundamental Strength with a -226.72% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -3.35
- The company has been able to generate a Return on Equity (avg) of 1.10% signifying low profitability per unit of shareholders funds
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
EUR 95 Million ()
NA (Loss Making)
NA
0.00%
0.30
-70.30%
6.92
Revenue and Profits:
Net Sales:
21 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.59%
0%
-20.59%
6 Months
33.66%
0%
33.66%
1 Year
32.35%
0%
32.35%
2 Years
16.13%
0%
16.13%
3 Years
-34.94%
0%
-34.94%
4 Years
-67.17%
0%
-67.17%
5 Years
-56.63%
0%
-56.63%
Vita 34 AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
34.38%
EBIT Growth (5y)
-223.43%
EBIT to Interest (avg)
-3.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
1.38
Tax Ratio
37.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.13%
ROE (avg)
1.10%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.98
EV to EBIT
-10.95
EV to EBITDA
-86.46
EV to Capital Employed
7.72
EV to Sales
1.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-70.49%
ROE (Latest)
-74.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
21.50
22.10
-2.71%
Operating Profit (PBDIT) excl Other Income
1.70
2.60
-34.62%
Interest
0.40
0.90
-55.56%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.80
-0.70
214.29%
Operating Profit Margin (Excl OI)
-19.90%
21.70%
-4.16%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.71% vs 0.91% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 214.29% vs 93.64% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
82.20
77.10
6.61%
Operating Profit (PBDIT) excl Other Income
-2.90
4.70
-161.70%
Interest
1.40
1.70
-17.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.30
-2.00
-515.00%
Operating Profit Margin (Excl OI)
-149.50%
-49.50%
-10.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.61% vs 11.90% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -515.00% vs 92.70% in Dec 2023
About Vita 34 AG 
Vita 34 AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






